Takeda Pharmaceuticals Korea is quickening its steps to receive reimbursement listing for ‘Obizur,’ its treatment for bleeding episodes in patients with acquired hemophilia A (AHA).

According to industry sources, Takeda Pharmaceuticals Korea’s bleeding treatment for adults with acquired hemophilia A may soon be introduced for deliberation at the Health Insurance Review and Assessment Service’s Drug Reimbursement Evaluation Committee meeting in August.

As reimbursement evaluations for Obizur have been ongoing immediately after receiving approval in March, the reimbursement process is progressing relatively quickly. Obizur has been designated as an orphan drug in Korea in July 2021.